Adamas Pharmaceuticals Provides Data Update On ADS-5102 At The American Academy Of Neurology Annual Meeting

Share

Adamas Pharmaceuticals Provides Data Update On ADS-5102 At The American Academy Of Neurology Annual Meeting (via PR Newswire)

Positive Clinician-Reported Patient Assessments Consistent with Earlier Findings Reported with ADS-5102 EMERYVILLE, Calif., April 30, 2014 /PRNewswire/ -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a specialty pharmaceutical company, today presented…

Click for a printer friendly version

Back to top